Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK510 in Advanced Gastric and Colorectal Cancer
NCT07166263Phase 1Recruiting
- Sponsor
- Base Therapeutics
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK510 in gastric cancer (GC) and colorectal cancer (CRC) (2 arms), sponsored by Base Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 6 weeks, Overall Response Rate at 6 weeks and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
NK510
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07166263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166263.